John C. Riches

Charterhouse Square
London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

Enhancing Immunotherapy in Diffuse Large B-Cell Lymphoma: The Synergistic Potential of Metabolic Checkpoint Inhibitors and Immunomodulation.

Enhancing Immunotherapy in Diffuse Large B-Cell Lymphoma: The Synergistic Potential of Metabolic Checkpoint Inhibitors and Immunomodulation.

Journal: OncoTargets and therapy

Published: November 15, 2025

Analysis of volatile organic compounds in exhaled breath of blood cancer patients identifies products of lipid peroxidation as biomarkers for lymphoma detection.

Analysis of volatile organic compounds in exhaled breath of blood cancer patients identifies products of lipid peroxidation as biomarkers for lymphoma detection.

Journal: HemaSphere

Published: February 13, 2025

PHGDH is required for germinal center formation and is a therapeutic target in MYC-driven lymphoma.

PHGDH is required for germinal center formation and is a therapeutic target in MYC-driven lymphoma.

Journal: The Journal of clinical investigation

Published: February 15, 2024

Taking the Next Step in Double Refractory Disease: Current and Future Treatment Strategies for Chronic Lymphocytic Leukemia.

Taking the Next Step in Double Refractory Disease: Current and Future Treatment Strategies for Chronic Lymphocytic Leukemia.

Journal: OncoTargets and therapy

Published: November 01, 2023

The Evolution of Therapies Targeting Bruton Tyrosine Kinase for the Treatment of Chronic Lymphocytic Leukaemia: Future Perspectives.

The Evolution of Therapies Targeting Bruton Tyrosine Kinase for the Treatment of Chronic Lymphocytic Leukaemia: Future Perspectives.

Journal: Cancers

Published: March 22, 2023

Spotlight on New Therapeutic Opportunities for MYC-Driven Cancers.

Spotlight on New Therapeutic Opportunities for MYC-Driven Cancers.

Journal: OncoTargets and therapy

Published: March 04, 2023

Editorial: Biology and treatment of high-risk CLL.

Editorial: Biology and treatment of high-risk CLL.

Journal: Frontiers in oncology

Published: November 28, 2022

Opinion: What defines high-risk CLL in the post-chemoimmunotherapy era?

Opinion: What defines high-risk CLL in the post-chemoimmunotherapy era?

Journal: Frontiers in oncology

Published: November 23, 2022

Advances in Understanding of Metabolism of B-Cell Lymphoma: Implications for Therapy.

Advances in Understanding of Metabolism of B-Cell Lymphoma: Implications for Therapy.

Journal: Cancers

Published: October 14, 2022

The Use of Breath Analysis in the Management of Lung Cancer: Is It Ready for Primetime?

The Use of Breath Analysis in the Management of Lung Cancer: Is It Ready for Primetime?

Journal: Current oncology (Toronto, Ont.)

Published: August 30, 2022

2022 update on the clinical outcome of coronavirus disease 2019 in haemato-oncology patients.

2022 update on the clinical outcome of coronavirus disease 2019 in haemato-oncology patients.

Journal: Leukemia research

Published: June 07, 2022

Cessation of Ciprofloxacin Prophylaxis in Hemato-Oncology Patients.

Cessation of Ciprofloxacin Prophylaxis in Hemato-Oncology Patients.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: December 05, 2021

Showing 1-12 of 36

Last Updated: 09/26/2026